Ganaxolone (Epilepsy)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Classification of Seizures 14
3.2 Etiology and Pathophysiology 15
3.2.1 Etiology 15
3.2.2 Pathophysiology 18
3.2.3 Prognosis 23
3.2.4 Quality of Life 24
4 Disease Management 25
4.1 Diagnosis 25
4.2 Treatment Guidelines 26
4.3 Clinical Practice 27
5 Competitive Assessment 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 35
6 Opportunity and Unmet Need 38
6.1 Overview 38
6.2 Unmet Needs 39
6.2.1 Refractory Epilepsy 39
6.2.2 Safety/Side Effect Profiles 40
6.2.3 Curative/Disease-Modifying Agents 41
6.2.4 Predictive Tools and Need for More Directed Treatments 41
6.2.5 Improved Preclinical Models and Clinical Trial Paradigms 42
6.2.6 Treatment Gap 43
6.3 Unmet Needs Gap Analysis 44
6.4 Opportunities 45
6.4.1 Disease-Modifying Agents 45
6.4.2 Improved Preclinical Models and Clinical Trial Paradigms 45
6.4.3 Treatment Gap 45
7 Pipeline Assessment 46
7.1 Overview 46
7.2 Strategic Pipeline Assessment 46
7.3 Pipeline by Phases of Development 47
7.3.1 Phase III Pipeline 47
7.3.2 Phase III Pipeline – Reformulations/New Delivery Systems 48
7.3.3 Phase IIb Pipeline 48
7.3.4 Phase II Pipeline 49
7.3.5 Phase I Pipeline 49
7.3.6 Preclinical Pipeline 50
7.3.7 Discovery Pipeline 51
7.4 Pipeline by Mechanism of Action 51
7.5 Promising Drugs in Clinical Development 53
8 Ganaxolone 54
8.1 Overview 54
8.2 Efficacy 55
8.3 Safety 55
8.4 Dosing and Formulation 56
8.5 Potential Clinical Positioning 56
8.6 Potential Commercial Positioning 56
8.7 Pricing and Reimbursement 56
8.8 SWOT Analysis 57
8.9 Forecast 57
9 Appendix 58
9.1 Bibliography 58
9.2 Abbreviations 61
9.3 Methodology 63
9.4 Forecasting Methodology 63
9.4.1 Prevalent Epilepsy Patients 63
9.4.2 Percent Drug-Treated Patients 64
9.4.3 General Pricing Assumptions 64
9.4.4 Generic Erosion 65
9.4.5 Pricing of Pipeline Agents 65
9.5 Physicians and Specialists Included in this Study 65
9.6 Primary Research – Prescriber Survey 66
9.7 About the Authors 67
9.7.1 Authors 67
9.7.2 Global Head of Healthcare 68
9.8 About GlobalData 69
9.9 Contact Us 69
9.10 Disclaimer 69